BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 33640020)

  • 1. Is rituximab effective for systemic sclerosis? A systematic review and meta-analysis.
    de Figueiredo Caldas MMV; de Azevedo KPM; de França Nunes AC; de Oliveira VH; Pimenta IDSF; de Araújo IDT; Neto FAB; da Silveira Gonçalves de Oliveira AK; Piuvezam G
    Adv Rheumatol; 2021 Feb; 61(1):15. PubMed ID: 33640020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab in systemic sclerosis: A protocol for systematic review.
    Caldas MMVF; Neto FAB; Azevedo KPM; Pimenta IDSF; Oliveira AKDSG; Piuvezam G
    Medicine (Baltimore); 2019 Sep; 98(38):e17110. PubMed ID: 31567948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab in the treatment of systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis.
    Goswami RP; Ray A; Chatterjee M; Mukherjee A; Sircar G; Ghosh P
    Rheumatology (Oxford); 2021 Feb; 60(2):557-567. PubMed ID: 33164098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease.
    Ebata S; Yoshizaki A; Fukasawa T; Miura S; Takahashi T; Sumida H; Asano Y; Sato S
    J Dermatol; 2019 Nov; 46(11):1006-1013. PubMed ID: 31502326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of rituximab on lung and skin involvement in systemic sclerosis: a systematic review and metaanalysis.
    Borrirukwisitsak S; Tantayakom P; Katchamart W
    Clin Rheumatol; 2021 Jul; 40(7):2779-2789. PubMed ID: 33428098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature.
    Giuggioli D; Lumetti F; Colaci M; Fallahi P; Antonelli A; Ferri C
    Autoimmun Rev; 2015 Nov; 14(11):1072-8. PubMed ID: 26209905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclophosphamide for connective tissue disease-associated interstitial lung disease.
    Barnes H; Holland AE; Westall GP; Goh NS; Glaspole IN
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD010908. PubMed ID: 29297205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of Rituximab in systemic sclerosis: A systematic review and meta-analysis.
    Tang R; Yu J; Shi Y; Zou P; Zeng Z; Tang B; Wang Y; Ling G; Luo M; Xiao R
    Int Immunopharmacol; 2020 Jun; 83():106389. PubMed ID: 32172205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of rituximab in the treatment of systemic sclerosis: A literature review.
    Yoshifuji H; Yomono K; Yamano Y; Kondoh Y; Yasuoka H
    Mod Rheumatol; 2023 Nov; 33(6):1068-1077. PubMed ID: 37053127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of rituximab in connective tissue disease-associated interstitial lung disease: A systematic review and meta-analysis.
    Xing NS; Fan GZ; Yan F; Liu YP; Zhang R
    Int Immunopharmacol; 2021 Jun; 95():107524. PubMed ID: 33721757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis.
    Macrea M; Ghazipura M; Herman D; Barnes H; Knight SL; Silver RM; Montesi SB; Raghu G; Hossain T
    Ann Am Thorac Soc; 2024 Feb; 21(2):317-327. PubMed ID: 37772987
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
    Jordan S; Distler JH; Maurer B; Huscher D; van Laar JM; Allanore Y; Distler O;
    Ann Rheum Dis; 2015 Jun; 74(6):1188-94. PubMed ID: 24442885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Percentage of residual B cells after 2 weeks of rituximab treatment predicts the improvement of systemic sclerosis-associated interstitial lung disease.
    Ebata S; Yoshizaki A; Fukasawa T; Yoshizaki-Ogawa A; Asano Y; Kashiwabara K; Oba K; Sato S
    J Dermatol; 2022 Jan; 49(1):179-183. PubMed ID: 34661314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease.
    Daoussis D; Melissaropoulos K; Sakellaropoulos G; Antonopoulos I; Markatseli TE; Simopoulou T; Georgiou P; Andonopoulos AP; Drosos AA; Sakkas L; Liossis SN
    Semin Arthritis Rheum; 2017 Apr; 46(5):625-631. PubMed ID: 27839742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of rituximab therapy in patients with systemic sclerosis disease (SSc): systematic review and meta-analysis.
    Moradzadeh M; Aghaei M; Mehrbakhsh Z; Arab-Bafrani Z; Abdollahi N
    Clin Rheumatol; 2021 Oct; 40(10):3897-3918. PubMed ID: 33796953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab on lung, skin, and joint involvement in patients with systemic sclerosis: A case series study and review of the literature.
    Yarkan Tuğsal H; Zengin B; Kenar G; Önen F; Birlik M
    Int J Rheum Dis; 2022 Jul; 25(7):755-768. PubMed ID: 35535670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy with rituximab and mycophenolate mofetil in systemic sclerosis. A single-centre case series study.
    Fraticelli P; Fischetti C; Salaffi F; Carotti M; Mattioli M; Pomponio G; Gabrielli A
    Clin Exp Rheumatol; 2018; 36 Suppl 113(4):142-145. PubMed ID: 30277864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid decrease of serum surfactant protein-D levels predicts the reactivity of rituximab therapy in systemic sclerosis-associated interstitial lung disease.
    Ebata S; Yoshizaki A; Fukasawa T; Asano Y; Oba K; Sato S
    J Dermatol; 2020 Jul; 47(7):796-800. PubMed ID: 32383266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab for the therapy of systemic sclerosis: a series of 10 cases in a single center.
    Vilela VS; Maretti GB; Gama LM; Costa CH; Rufino RL; Levy RA
    Rev Bras Reumatol Engl Ed; 2016; 56(5):458-463. PubMed ID: 27692396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of rituximab for the treatment of refractory systemic sclerosis associated calcinosis: A case series and systematic review of the literature.
    Narváez J; Pirola JP; LLuch J; Juarez P; Nolla JM; Valenzuela A
    Autoimmun Rev; 2019 Mar; 18(3):262-269. PubMed ID: 30639647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.